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SUPPLEMENT ARTICLE
Integrated and Gender-Affirming Transgender
Clinical Care and Research
Sari L. Reisner, ScD,* Asa Radix, MD, MPH,† and Madeline B. Deutsch, MD, MPH‡
Abstract: Transgender (trans) communities worldwide, particu-
larly those on the trans feminine spectrum, are disproportionately
burdened by HIV infection and at risk for HIV acquisition/
transmission. Trans individuals represent an underserved, highly
stigmatized, and under-resourced population not only in HIV
prevention efforts but also in delivery of general primary medical
and clinical care that is gender afﬁrming. We offer a model of
gender-afﬁrmative integrated clinical care and community research
to address and intervene on disparities in HIV infection for
transgender people. We deﬁne trans terminology, brieﬂy review
the social epidemiology of HIV infection among trans individuals,
highlight gender afﬁrmation as a key social determinant of health,
describe exemplar models of gender-afﬁrmative clinical care in
Boston MA, New York, NY, and San Francisco, CA, and offer
suggested “best practices” for how to integrate clinical care and
research for the ﬁeld of HIV prevention. Holistic and culturally
responsive HIV prevention interventions must be grounded in the
lived realities the trans community faces to reduce disparities in
HIV infection. HIV prevention interventions will be most effective
if they use a structural approach and integrate primary concerns of
transgender people (eg, gender-afﬁrmative care and management
of gender transition) alongside delivery of HIV-related services
(eg, biobehavioral prevention, HIV testing, linkage to care,
and treatment).
Key Words: HIV, transgender, prevention, models of clinical care,
health inequities
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OVERVIEW
Despite the disproportionate burden of HIV infection
facing transgender communities, particularly for transgender
feminine spectrum people worldwide,1 transgender individuals
continue to represent an underserved, highly stigmatized, and
under-resourced population in both general clinical care and
HIV prevention services. The aim of this article is to describe
and present a model of gender-afﬁrmative and integrated clinical
care and community research for transgender people to address
and intervene on disparities in HIV infection. To do this, we ﬁrst
deﬁne terminology pertaining to transgender people, brieﬂy
review the epidemiology of HIV infection and risks in trans-
gender communities, describe exemplar models of gender-
afﬁrmative clinical care for transgender people in Boston MA,
New York, NY, and San Francisco, CA, and offer suggested
“best practices” for integrating clinical care and research in trans
health. It is our assertion that any holistic HIV prevention
intervention for transgender people will need to address clinical
issues and integrate primary concerns of transgender people (eg,
gender-afﬁrmative care, management of gender transition, and
medical gender afﬁrmation) alongside delivery of HIV-related
services (biobehavioral prevention, testing, linkage to care, and
treatment). Integration of gender-afﬁrmative clinical care and
research represents a holistic and structural approach to intervene
on HIV disparities for transgender people.
TERMINOLOGY
Transgender and gender nonconforming people (trans
or gender minority) have a gender identity or expression that
differs from their assigned sex at birth.2 Trans people are
a diverse group. There is varied terminology used to describe
gender minority people in different geographic and cultural
contexts and settings; language and terms also continuously
evolve and change to describe trans deﬁnitions and trans
identities over time. In this article, we use the term trans
feminine to refer to individuals assigned a male sex at birth who
identify as women, female, male to female, transgender women,
trans women, transfemale, or other diverse culturally or
contextually speciﬁc gender identities on the trans feminine
spectrum. Trans masculine denotes individuals assigned a female
sex at birth who identify as men, male, female to male,
transgender men, trans men, transmale, or another heterogeneous
gender identity on the trans masculine spectrum. The terms trans
feminine and trans masculine are used to not only include
western deﬁnitions of “transgender women” and “transgender
men” but also to integrate the diverse and heterogeneous
terminologies and conceptualizations of transgender individuals
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globally, including those who may not fully conform to binary
(male/female, man/woman) gender categories and who still may
be at risk of HIV acquisition or transmission. We use nonbinary
to refer to transgender or gender nonconforming people who
may not identify with a male/female binary system of gender
categorization (eg, genderqueer, bigender, and agender).
SOCIAL EPIDEMIOLOGY OF HIV INFECTION
AMONG TRANS PEOPLE
Globally, HIV infection is devastatingly high among trans
feminine people. A meta-analysis of global studies with
laboratory-conﬁrmed HIV infection data and at least 50
participants documented an HIV prevalence of 19% among
trans feminine individuals and a 49-fold increased odds of HIV
infection compared with cisgender (ie, nontransgender) adults of
reproductive age.1 HIV infection data are scarce for trans
masculine individuals.3 A 2016 review found only 10 quanti-
tative studies (all in North America) with laboratory-conﬁrmed
HIV serostatus among trans masculine people; amont these,
documented HIV seroprevalences were 0%, 2.2%, 3.0%, and
4.3% (1 of 23 individuals).4 There exist few HIV infection data
about nonbinary trans people; these individuals are underrepre-
sented in current clinical and epidemiologic research.
As with other key populations, risk for HIV acquisition
or transmission in trans people is complex. HIV risk for trans
people has been attributed to intersecting syndemics of
biopsychosocial factors (eg, biological, psychological, social,
and structural) occurring across multiple levels of inﬂuence,
ranging from the individual, interpersonal, community and
network, and societal levels.4–8 A core driver of HIV risk for
trans people is pervasive stigma which leads to HIV-related
vulnerabilities through pathways of social and economic
exclusion and marginalization, particularly for trans feminine
individuals.1,9 For example, social marginalization and employ-
ment discrimination can lead trans feminine populations to
engage in transactional or survival sex (ie, sex work) with
higher economic incentives offered by clients for condomless
anal sex acts.10 Trans masculine individuals, particularly those
who are gay, bisexual, same-gender loving, queer, or have sex
with cisgender males are also an at-risk group, potentially
exposed to the double stigma of being both sexual and
gender minorities.11 Attending to the trans-speciﬁc biological,
social, and behavioral factors which drive HIV vulnerabilities
will be crucial to HIV prevention interventions that seek to
curb HIV incidence in transgender people.12
GENDER AFFIRMATION AS A KEY SOCIAL
DETERMINANT OF TRANS HEALTH
In 2013, the Diagnostic and Statistical Manual of Mental
Disorders-5 (DSM-5) was revised and gender identity disorder
(GID) was changed to gender dysphoria, a diagnostic criteria
reﬂecting the psychological distress that occurs due to gender
and sex discord.13 Gender dysphoria is characterized by
clinically signiﬁcant distress or impairment in social, occupa-
tional, or other important areas of functioning associated with
having a gender identity or expression different than that sex
assigned at birth and/or gender roles typically associated with
that sex. Alleviation of symptoms of clinically signiﬁcant
distress resulting from gender dysphoria (ie, “treatment”)
focuses on afﬁrming the person’s felt and/or expressed gender.
Gender afﬁrmation is thus a critical component of the health
and well-being of trans individuals and communities.
Gender afﬁrmation refers to the social process of being
recognized or afﬁrmed in one’s gender identity, expression,
and/or role.14 Although gender afﬁrmation can be theorized as
an inherently social process,14 it must necessarily also be
conceptualized as multidimensional with at least 4 core
constructs: social (choice of name and pronoun, interpersonal
and institutional acknowledgment and recognition), psycholog-
ical (internal felt sense of self-actualization, validation of
gendered self, internalized transphobia), medical (pubertal
blockers, hormones, surgery, other body modiﬁcation), and
legal (legal name change, legal change of gender marker
designation) (Fig. 1).11 There is no one single path to gender
afﬁrmation—no “one size ﬁts all” approach describes how trans
people afﬁrm their felt or expressed gender.15 Some trans
individuals pursue social but not medical gender afﬁrmation,
some pursue medical but not legal gender afﬁrmation, and so
on. Gender afﬁrmation sometimes, but not always, conforms to
binary categories of being female or male. Furthermore, gender
afﬁrmation does not require linearly following a discrete series
of “transition” events—it is conceptualized as an ongoing
process throughout the lifecourse.
Gender afﬁrmation is a unique social determinant of
health that affects trans people’s lives. Lack of social and
psychological gender afﬁrmation has been shown to
adversely impact health care utilization behaviors among
transgender people, including delaying preventive health care
screenings or avoiding needed clinical care when sick or
injured.16,17 Medical gender afﬁrmation (eg, hormones) has
been shown to reduce mental health risks18,19 and improve
quality of life for transgender people.20,21 Although the impact
of gender afﬁrmation on overall health has not been studied,
FIGURE 1. Gender affirmation: process of being affirmed in
one’s gender identity. Four dimensions: social, psychological,
medical, and legal.
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provider anecdotes include reports of improvements in
a variety of health conditions including obesity and diabetes
after gender-afﬁrming care and interventions, as patients gain
a sense of self-worth and self-efﬁcacy and become more
invested in achieving and maintaining health.
In many countries and geographic contexts, medical
gender afﬁrmation is excluded from mainstream delivery or
primary care services for transgender people and thereby
relegated outside of the health care system. Lack of
knowledgeable health care providers combined with trans-
phobia and stigma in health care delivery systems may lead
transgender people to procure gender-afﬁrmative medical care
through informal peer or community networks,22–24 which
may increase risk of health complications (eg, lack of routine
monitoring of hormone levels, using higher than recommen-
ded dosages of hormones). Inability to legally afﬁrm gender
through legal documents (eg, government-issued identiﬁca-
tion) that match one’s gender identity can be a barrier to
accessing and receiving health care services, particularly
within socialized government supported and sponsored health
care systems. In most countries, transgender people cannot
obtain appropriate legal gender afﬁrmation documents and/or
are required to have genital surgery to be able to do so.25 This
lack of legal recognition leads to social, economic, and
political marginalization and economic exclusion which can
increase vulnerability to HIV.26
Gender afﬁrmation has been further implicated in HIV-
related outcomes. Lack of social gender afﬁrmation has been
shown to increase sexual risk for HIV acquisition or trans-
mission in both trans feminine14,27 and trans masculine
individuals.11,27 Medical mistrust due to previous experiences
of gender invalidation and transphobic-stigma in health care
settings is linked to low pre-exposure prophylaxis (PrEP)
acceptability among HIV-uninfected trans feminine individu-
als,28 to challenges with engagement and retention in HIV
treatment and care among trans feminine people living with
HIV,29,30 and with participation in HIV research trials.31
Prioritization of hormones for medical gender afﬁrmation over
other health concerns inﬂuences all aspects of the HIV
continuum of care, including PrEP acceptability,28 engagement
and retention in HIV treatment, and care.29,30 Adherence to
hormones has been shown to positively correlate with increased
viral load among transgender women living with HIV providing
further evidence that trans communities prioritize medical
gender afﬁrmation in daily life.32 Concerns regarding adverse
interactions between antiretroviral medications and hormones
are frequently cited barriers to PrEP acceptability and engage-
ment and retention in HIV treatment and care.28,29
GENDER-AFFIRMATIVE HEALTH CARE FOR
TRANS PEOPLE
Gender-afﬁrmative health care refers to care that is
sensitive, responsive, and afﬁrming to trans patients’ gender
identities and/or expressions (Fig. 2). Several US centers (eg,
Fenway Health in Boston, MA; Callen-Lorde Community
Health Center in New York City, NY; and the University of
California, San Francisco, CA) specialize in transgender
clinical care (Appendix 1). Through serving large numbers
of trans patients, these organizations have developed and
reﬁned models of gender-afﬁrmative care to meet trans
patients’ needs. Gender-afﬁrmative models are rooted in
a strength-based depathologization of human gender diversity
(transgender as “identity”), rather than a pathological per-
spective (transgender as “disorder”). These programs exem-
plify an approach to transgender clinical care, research, and
public health that can and should be implemented every-
where, no matter how many or how few transgender patients
a clinic or hospital or community center may see. In reality,
effective transgender care systems can be developed in any
setting, as long as this development is supported by institu-
tional will and is incorporated into the organization’s mission.
The bedrock of gender-afﬁrmative health care, including
HIV prevention and care services to address the HIV continuum
of care for trans people, is afﬁrming trans patients across social,
psychological, medical, and legal dimensions. Within the social
and psychological domains, referring to trans people respect-
fully, and with the appropriate pronoun and name, is a key
construct in the provision of gender-afﬁrming care. “Misgen-
dering” involves referring to a trans person using an incorrect
pronoun or name, and represents one of the most common
microaggressions experienced by trans people in clinical and
research settings.33,34 One way to prevent misgendering is rely
on gender-neutral language, such as “How may I help you
today?” instead of “How may I help you, sir?” or “Dr. Hope’s
11:30 a patient is here” rather than “he is here for his
appointment.” Staff can also use neutral “they” pronouns
instead of “she” or “he”; for example, “they are here for their
3:00 PM appointment.” While some may perceive this use as
grammatically incorrect, some language authorities and ofﬁcials
are beginning to formally recognize neutral pronouns.35 Under
no circumstances should any person ever be referred to as “it.”
Registration or intake forms and electronic health
records that routinely collect gender identity using a 2-step
method36,37 (current gender identity and assigned sex), as well
as chosen name and pronoun (“he/him/his,” “she/her/hers,”
“they/them/theirs”), are recommended. The 2-step method for
gender identity, as well as collection of sexual orientation
information, has been incorporated into the “Meaningful Use”
guidelines for electronic medical records published by the US
Department of Health and Human Services.38 Health care
systems should integrate this information into clinical care
from the moment a patient walks into the door. Name and
gender on government-issued identiﬁcation may or may not
be able to be changed, depending on the country and context.
Legal documents may have implications for health insurance
billing and claims, as well as ability to access certain medical
services. For example, medical services may be needed that
conﬂict with legal gender markers which can complicate
health insurance billing (eg, a female-to-male trans masculine
individual having a legal male gender marker and needing
a Pap test to screen for cervical cancer). Consultation with
local state laws and experts is recommended for solutions to
speciﬁc incidents as they arise. In the United States, a “code
45” modiﬁer can be used in cases of mismatch between legal
sex and a needed service.39
Medical gender afﬁrmation may include any combina-
tion of hormones, surgery, and other procedures such as hair
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removal or voice modiﬁcation. In addition to speciﬁc gender-
afﬁrming interventions, transgender people require the full
range of primary and specialty care. Because transgender
people may have a variety of organ conﬁgurations (someone
may have both a prostate and breasts, or ovaries but no uterus
or breasts), clinicians and researchers should take an organ-
based approach rather than relying on natal sex or gender
identity to deﬁne anatomy.
CLINICAL MANAGEMENT OF MEDICAL
GENDER AFFIRMATION
The most recent clinical and medical aspects of trans-
gender care have been outlined in version 7 of the Standards of
Care by the World Professional Association for Transgender
Health (WPATH).15,40 Transgender people seeking gender
afﬁrmation through the acquisition of secondary sex character-
istics of their identiﬁed gender may seek hormonal interven-
tions. The proportion of transgender people who opt to undergo
medical transition varies based on access and cost. In the United
States and Canada, hormone utilization among trans feminine
individuals is reported to be 43%–73%,24,41–43 with as high as
70% accessing hormones outside of the medical system.43–46
Nonbinary individuals are less likely to use hormonal therapy or
undergo gender-conﬁrming surgeries.41,47 Hormonal therapies
seem to be associated with improved quality of life and mental
health functioning; however, there have been no clinical trials or
long-term prospective studies.21,48,49
For trans feminine individuals, hormonal therapy usually
consists of estrogens and androgen blockers. Estrogen therapy
typically includes an oral, transdermal, or injected 17-beta
estradiol.15,50 Ethinyl estradiol (a common component of oral
contraceptives) is associated with high incidence of venous
thromboembolism51 and is no longer recommended in femi-
nizing regimens, but may be used by trans feminine individ-
uals outside of medical settings. There are many different
androgen blockers used for transition care. Spironolactone, an
aldosterone receptor antagonist, is frequently used in the United
States, whereas cyproterone acetate, a synthetic steroidal
antiandrogen with prostogenic properties, is predominantly
outside of the United States. Other blockers include
gonadotropin-releasing hormone analogs, eg, leuprolide ace-
tate; 5 alpha-reductase inhibitors, eg, ﬁnasteride; and proges-
tins. Trans masculine individuals who seek virilization typically
use injected or topical testosterone regimens. The choice of
hormones and route of administration are often based on
personal preference, age, and concurrent medical issues. There
have been no clinical trials to evaluate comparative safety and
efﬁcacy of hormones in transgender people. For trans feminine
people who have signiﬁcant cardiovascular risk factors,
including smoking and older age, transdermal estrogens are
recommended. There are no evidence-based recommendations
for the frequency or type of laboratory monitoring. Existing
guidelines for laboratory monitoring are based on expert
opinion and range from every 3 months to once a year,
depending on the length of time an individual has been
receiving hormones and concurrent medical conditions.50
In the context of coadministration of gender-afﬁrming
hormones and antiretroviral therapy (ART) either for treatment or
PrEP for HIV, no direct studies have been conducted. Studies of
interactions of oral contraceptives containing synthetic ethinyl
estradiol and various ART medications suggest that negative
effects of hormones on ART are limited to amprenavir,
unboosted fosamprenavir, and stavudine.52–55 Positive or negative
effects of ART on ethinyl estradiol levels may be more common
and might represent a barrier to adherence because trans feminine
individuals who perceive a negative impact on their gender
transition may exhibit reduced adherence or total discontinuation
of ART therapy29,56; pill burden may represent another factor
which leads to adherence to hormones, but not ART. The authors
of a recent subanalysis of trans feminine individuals in the iPrEx
study of PrEP opined that an observed association of hormone
therapy with lower drug levels was as a result of such behavioral
factors, rather than a pure biological interaction.57
With respect to gender-afﬁrming surgeries, for trans
feminine people may opt to undergo gonadectomy (orchi-
ectomy) and creation of a vagina, clitoris, and labia. The most
common vaginoplasty procedure uses penile and scrotal tissue
to create a skin-lined vaginal vault and vulva (penile inversion
vaginoplasty); much less common is an approach using
sigmoid colon to create a self-lubricating neovagina, with
drawbacks of higher rates of complication and a more invasive
FIGURE 2. Gender-affirmative health
care: health care that holistically attends
to transgender people’s physical, mental,
and social health needs and well-being
while respectfully affirming their gender
identity.
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procedure. Gender-afﬁrming surgeries for trans masculine
people include breast reduction, eg, bilateral double incision
or periareolar mastectomy, hysterectomy, and oophorectomy.
There are several procedures to construct the external genitalia,
including creation of a phallus (phalloplasty or metoidioplasty)
and/or scrotum (scrotoplasty with testicular implants). In
general, levels of satisfaction after gender-afﬁrming surgeries
are high,58,59 although trans feminine individuals who have
undergone vaginoplasty are more likely to meet criteria for
hypoactive sexual desire disorder than both nontransgender
women and transgender women who have not undergone
vaginoplasty.60,61 Trans masculine individuals experience high-
er rates of sexual desire after starting testosterone.60,62 No
studies have been conducted to determine changes in behavior
after genital surgery, for example, to assess whether trans
feminine individuals are more likely to have vaginal rather than
anal receptive sex after vaginoplasty.
Because the majority of vaginoplasties use the penile
inversion technique which results in a penile skin-lined
vagina, risk of transmission of HIV or of acquisition of
genital lesions is unknown,10 although infections with
gonorrhea and human papillomavirus (condyloma acumina-
ta) have been reported.63–67 Trans masculine individuals may
engage in receptive anal or vaginal sex and may continue to
engage in receptive anal sex even after genital reconstruc-
tion. The cervical epithelium changes with administration of
testosterone.68 It remains unknown whether hormone-
mediated changes to the genital tract in either trans feminine
or trans masculine individuals could impact risks for HIV or
other sexually transmitted infections.
CONNECTING TRANS CLINICAL CARE
AND RESEARCH
In the absence of solid evidence to inform “best
practices” for improving and connecting clinical care and
research programs in transgender health and medicine, we
propose the below framework of recommendations:
Ask the 2-Step Method (Gender Identity and
Assigned Sex at Birth) on Intake Forms and in
Electronic Health Records
Collect gender identity and assigned sex at birth data on
intake forms and electronic health records to promote gender-
afﬁrmative health care. Capturing gender identity data can
inform quality improvement efforts and create basic research
opportunities (ie, chart review studies to characterize the
patient population, prevalence, and distribution of patient
populations retained in care).
Co-Locate Services, Including Access to
Hormones and HIV Prevention, Testing, and
Linkage to HIV Care and Treatment Services
Wrap-around services are ideal in trans health care
provision, minimizing loss to follow-up and simplifying
service delivery. Integrating HIV-related services into
gender-afﬁrmative care is an especially effective clinical
strategy. For example, routine HIV testing can be imple-
mented as part of routine blood work for monitoring and
management of cross-sex hormones.
Partner With and Engage Local
Trans Communities
Engaging and involving trans communities in health
care delivery, programs, and interventions is critical to ensure
that services are gender afﬁrmative and responsive to
community health care needs. A local community involve-
ment process (eg, community advisory boards) should be
used to tailor clinical and research tools to local demographics
(ie, monolingual Spanish speaking trans feminine people in
Los Angeles have different concerns and approaches than
Black trans feminine people in Atlanta). Community mem-
bers should be involved in the formulation of research
questions and methods. The opportunity for community
feedback at all junctures (eg, grievance procedures, etc.) will
build trust.
Use a Multidisciplinary Team Approach to
Clinical Care and Research
Multidisciplinary team approaches to clinical care and
research are an integrated model of gender-afﬁrmative service
delivery for trans people. Regular team meetings that
integrate clinical and research teams will help to ensure
coordination and integration of trans health care and the goal
of achieving health equity.
Design all Clinical Tools and Research
Assessments to be Gender Affirming
Clinical tools (eg, registration forms) and research
assessments (eg, surveys) should be gender afﬁrming.
Care should be taken to ensure that all tools and assess-
ments are culturally responsive for trans people. Having
trans community members be part of the design of tools
and assessments, review before implementation, and pilot
test is critical. Always give participants the opportunity
to provide feedback on clinical care and research,
including instruments and surveys (eg, use an open-
ended feedback ﬁeld at end of survey for participants to
provide feedback).
Ensure that Clinical Care and Research are
Responsive to the Social Contexts and Lived
Realities of Local Trans Populations
Trans communities face social and economic exclusion.
Gender-afﬁrmative health care that is contextually informed
will be most responsive to community needs. This includes
ﬂexible scheduling and hours; trans staff and providers so
trans people “see themselves” in clinical and research staff;
multiple contacts to help retain trans individuals in clinical
care and research (eg, friends and family contacts); multiple
modes of communication for contacts (eg, phone, text, social
media, and e-mail).
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Use Peer-to-Peer Methods to Recruit and
Retain Participants in Clinical Care
and Research
Clinical care infrastructures can be used as a foundation
for other services. For example, wrap-around services such as
peer health navigation, patient advocacy, and case manage-
ment can improve patient engagement and retention in care
and research.
Create a Pipeline of Trans Clinicians
and Researchers
Clinical and research training opportunities in transgender
medicine, epidemiology, and public health (eg, residency
programs, postdocs, grad student mentors) are greatly needed.
Although transgender clinicians and researchers encounter
numerous professional barriers and biases, a transgender identity
is not currently recognized by the US National Institutes of
Health (NIH) as an under-represented minority for the purposes
of accessing funding and training programs. Increased recogni-
tion of nontraditional investigator career paths will also expand
the range of opportunities for transgender-identiﬁed clinicians
and investigators.
THE WAY FORWARD: INTEGRATION FOR
GENDER AFFIRMATION
Gender afﬁrmation is a key ingredient to address the
needs of transgender people who are at risk for HIV
worldwide. Health care systems and clinical settings should
consider social, psychological, medical, and legal constructs
of gender afﬁrmation in clinical care and research. Holistic
and culturally responsive HIV prevention interventions must
be grounded in the lived realities faced by the transgender
community to reduce disparities in HIV infection, particularly
the need for gender-afﬁrmative medical care. Addressing
structural factors facing transgender people, particularly
stigma and transphobia in health care settings, is necessary
to increase uptake of the full HIV continuum of care (eg,
prevention, testing, and linkage to care) for the transgender
population. Training of health care providers in medical
gender afﬁrmation and improving systems of health care
delivery to be gender afﬁrmative will be integral components
of any strategy to mitigate HIV incidence.
Meaningful engagement of local, national, and global
transgender communities will be paramount to ensure respon-
siveness of interventions and programs, as well as to increase
trust and reciprocity between clinicians, researchers, patients,
and participants. Addressing disparities in HIV infection and
achieving health equity for transgender people necessitate an
integrated and gender-afﬁrming model of clinical care and
research that uses a participatory population perspective69 to
work “with” not “on” communities.70 This means involving
transgender people in all aspects of clinical care and research.
Implementation science research71 may be well suited to
implement and test biobehavioral interventions, such as PrEP
and early antiretroviral medication initiation, as part of
a comprehensive package of evidence-based prevention
interventions linked to gender-afﬁrmative care for transgender
people. Such interventional efforts will be maximally respon-
sive if they attend to the multiple health care needs of
transgender people outside of HIV infection.
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APPENDIX 1. GENDER-AFFIRMATIVE MODELS
OF TRANS CARE AND RESEARCH
Fenway Health, Boston, MA
Founded in 1971 as a grassroots health clinic in Boston, MA, Fenway
Health is a federally qualiﬁed community health center specializing in lesbian,
gay, bisexual, and transgender (LGBT) health care.69 Fenway offers accessible,
patient-centered, gender-afﬁrmative care for transgender individuals philosoph-
ically grounded in a model where gender afﬁrmation (eg, cross-sex hormone
therapy) is a routine part of primary care service delivery. Fenway uses an
informed consent model of care which removes unnecessary barriers to
hormone therapy for trans patients, including restrictions specifying prolonged
mental health evaluations and “real life tests” (ie, living full-time in one’s self-
identiﬁed gender) to obtain hormone therapy, that had long been embedded in
existing standards of care. Trans patients complete a hormone readiness
assessment, but mental health counseling is not automatically required. In
1983, Fenway Health initiated one of the ﬁrst community-based HIV research
programs, and The Fenway Institute (TFI) has continued to grow in scope and
broaden its mission: to make life healthier for those who are LGBT, people
living with HIV/AIDS, and the larger community through research and
evaluation, education and training, and public health advocacy.70 TFI has more
than 12 active biobehavioral and epidemiological research protocols focused
speciﬁcally on the health of trans people, including HIV prevention studies with
trans feminine72,73 and trans masculine youth.74
Callen-Lorde Community Health Center, New
York City, NY
Callen-Lorde Community Health Center is a federally qualiﬁed
community health center with a mission to provide quality, sensitive medical
and related services targeted to New York’s lesbian, gay, bisexual, and
transgender (LGBT) communities, including those living with HIV/AIDS.
The health center began when 2 volunteer-staffed, grassroots STD clinics that
predominantly treated gay men and transgender women, merged in 1983. The
health center is likely one of the largest outpatient practices in transgender
health in the nation, serving over 3000 transgender and gender nonconform-
ing patients. Callen-Lorde’s facilities are designed for transgender sensitivity,
including trans-inclusive registration forms, gender-neutral bathrooms and
trans-afﬁrmative signage and imagery, and trans-identiﬁed staff. Callen-Lorde
pioneered early adoption of a customized electronic health record that allows
appropriate documentation of the diversity of identities and anatomy among
transgender patients. The Trans Community Advisory Board reviews services
to ensure that these are accountable to community-based standards of cultural
competence. Transgender health is embedded in a primary care model. All
primary care providers provide comprehensive transgender health care,
including hormone therapy, using the Informed Consent Model that removes
unnecessary restrictions (eg, real life experience and mandatory mental health
evaluations) to hormone access. The center has onsite care coordination and
legal services to assist with name changes, housing, and insurance navigation
to address structural barriers to care. The center provides low cost or free
hormones and education programs, such as Hormone 101, self-injection
education, groups for trans feminine and trans masculine youth and adults,
and community health forums “Trans Out Loud.” Callen-Lorde also provides
LGBT trainings to external health facilities, with the goal to increase provider
knowledge and clinical skills caring for transgender communities.75 Since
2010, the center has participated in clinical research, mainly focusing on
behavioral and biomedical HIV prevention interventions among MSM and
transgender populations.
Transgender Care Navigation Program,
University of California, San Francisco (UCSF),
San Francisco, CA
The University of California, San Francisco is a world-recognized
leader in biomedical research and academic medicine. The Transgender
Care Navigation Program represents a collaboration between the UCSF
National Center of Excellence in Women’s Health and the Center of
Excellence for Transgender Health. The program was launched in 2015 as
a multidisciplinary network of primary care and specialty providers who
provide a range of medical, surgical, and vocal health care to children and
adults. A dedicated transgender care navigator serves as a central hub for
new patients and referrals between specialties. The navigator oversees
insurance authorizations and assists with preoperative assessments and
preparation. Providers collaborate on individual cases to optimize care and
preparation for surgeries. A program website provides information for both
patients and referring providers. As a large tertiary referral center, UCSF
draws patients from within a several hundred mile radius; hormone therapy
can be provided by telemedicine. Patients seeking hormone therapy can
also receive HIV care and general primary care from the same provider;
others who have outside primary and/or HIV care can be seen speciﬁcally
for hormone therapy consultations. In the ﬁrst 6 months of operation, the
program received inquiries from more than 400 transgender individuals
seeking care.
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